Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
et al., Viruses, doi:10.3390/v14040841 (Review)
Review of lethal mutagenesis for RNA viruses, as used by molnupiravir, favipiravir, and ribavirin. Authors note the potential for permanently modifying the genomes of patients while causing teratogenicity or embryotoxicity, and the potential of creating novel virus variants with increased pathogenicity and transmissibility.Authors recommend a registry of patients for long-term monitoring of potential adverse effects, including genetic, carcinogenic, teratogenic, and embryotoxic damage.
Hadj Hassine et al., 18 Apr 2022, peer-reviewed, 3 authors.
Contact:
lmenendez@cbm.csic.es (corresponding author), hadj_hassine_ekbell@yahoo.fr, benmhadhebmanel@yahoo.fr.
hadjhassine
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.